lasmiditan
lasmiditan: sourced relationships with 1 company · 2 clinical trials tracked · 1 FDA decision.
lasmiditan evidence translation
What we can confirm
1 FDA record · 2 tracked trials
What it means
What to watch
Prepared research question
How could lasmiditan → LLY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ELI LILLY & Co (LLY) Reported 2019-10-11 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (2)
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
Primary endpoint: Number of Participants With at Least One Treatment Emergent Adverse Events (TEAEs)
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Primary endpoint: Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-Dose
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with lasmiditan?
lasmiditan has dated SEC/FDA relationship records for ELI LILLY & Co.
How many clinical trials involve lasmiditan?
BioSniper tracks 2 clinical trials involving lasmiditan.
What is lasmiditan's latest FDA decision?
The most recent tracked FDA decision for lasmiditan is Approval for 1 INDICATIONS AND USAGE REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. REYVOW ® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine., dated October 11, 2019.